Thermo Fisher Scientific announced the expansion of its central laboratory operations in Kentucky, USA. With this move, the company’s PPD clinical research business will almost double its laboratory footprint in the region.

Asahi Kasei Medical's subsidiary Bionova Scientific has plans to launch a plasmid DNA business and for this it will develop a new facility in Texas, USA. The unit is scheduled to begin in the first quarter of 2025 for process development and later in 2025 for GMP manufacturing.

Under a definitive agreement signed between Merck and Mirus Bio, Merck will takeover Life Science company Mirus Bio for 600 million dollars. The move is expected to advance Merck’s integrated offering for viral vector manufacturing.

The National Research Foundation has funded 36 million dollars to the National University of Singapore’s Mechanobiology Institute for developing biomedical innovations for infertility, muscle loss and cancer.

The new Crispr-based gene-editing tool – AsCas12f is an enzyme which is compact and has a strong potential to treat genetic disorders of patients.

Scientists at .NeuroRestore, Switzerland, report in Science that they have developed a gene therapy that was proven in mice to stimulate nerve regrowth across spinal cord injuries and guide nerves to reconnect to their natural targets to restore mobility.

Researchers have revealed that gene therapy might have the potential to repair neural connections of patients suffering from Hurler syndrome, a rare brain disorder. They have already demonstrated this by experimenting on mice with the brain disorder.

AGC Biologics’ expanded development and production site includes single-use bioreactors which will help to meet the rising demands for GMP viral vector manufacturing projects. With this, the firm can also assist companies for in–vivo end ex-vivo gene therapy applications as well as manufacture adeno-associated and lentiviral vectors.

Waters Corporation announced it has completed its acquisition of Wyatt Technology, a pioneer in innovative light scattering and field-flow fractionation instruments, software, accessories, and services. With the acquisition of Wyatt, Waters wants to accelerate its ability to build a high-growth business in bioanalytical characterization for new modalities.

Under the collaboration between Trakcel and Lonza, both the parties have successfully combined Trakcel’s cell orchestration platform Ocellos and Lonza’s manufacturing Moda-Es(R) platform. This means that critical manufacturing steps, checks and data will flow directly into the Chain of Custody and Chain of Identity within the cell and gene therapy supply chain.